Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Air Liquide SA | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Continuous positive airway pressure (CPAP) is the first-line treatment for obstructive sleep apnea syndrome (OSA). It consists of a pressure generator connected to a mask applied to the patient's face. CPAP treatment is restrictive, and nearly a quarter of patients abandon it over the long term. Various factors can influence adherence to CPAP therapy, including adverse events associated with the mask. However, it is clear that compliance with CPAP treatment, even if it has tended to improve over the last 30 years, is still sub-optimal.
The "Air Liquide Medical Systems" company has developed a mask that aims to improve comfort and ease of use for the patient. This leaky nasal mask has a "silent" intentional leak port, which significantly reduces the noise caused by the escape of air. The noise associated with intentional leakage is one of the discomforts reported by patients and their spouses. In addition, this mask is equipped with a new generation headgear with adjustment indicators to assist the patient in fitting the mask. Optimal headgear fit is a prerequisite for comfort during treatment, as it reduces unintentional leakage.
The main objective is to evaluate, through a questionnaire, the comfort and general appreciation of a nasal mask equipped with a silent leak system and a headgear with adjustment aids, of patients with OSA treated with CPAP.
Secondary objectives are :
Continuous positive airway pressure (CPAP) is the first-line treatment for obstructive sleep apnea syndrome (OSA). It consists of a pressure generator connected to a mask applied to the patient's face. CPAP treatment is restrictive, and nearly a quarter of patients abandon it over the long term. Various factors can influence adherence to CPAP therapy, including adverse events associated with the mask. Unintentional leaks, i.e. a leak between the pressure generator and the patient's upper airway, are among the most frequent. Therefore, optimizing the choice of mask is one of the main means used by medical-technical providers, in charge of installing CPAP and its technical follow-up at home. In order to cover the needs and anatomical particularities of the OSA patient population treated with CPAP, a large number of mask types and sizes are currently available on the market. However, it is clear that compliance with CPAP treatment, even if it has tended to improve over the last 30 years, is still sub-optimal.
The "Air Liquide Medical Systems" company has developed a mask that aims to improve comfort and ease of use for the patient. This leaky nasal mask has a "silent" intentional leak port, which significantly reduces the noise caused by the escape of air. The noise associated with intentional leakage is one of the discomforts reported by patients and their spouses. In addition, this mask is equipped with a new generation headgear with adjustment indicators to assist the patient in fitting the mask. Optimal headgear fit is a prerequisite for comfort during treatment, as it reduces unintentional leakage.
The main objective is to evaluate, through a questionnaire, the comfort and general appreciation of a nasal mask equipped with a silent leak system and a headgear with adjustment aids, of patients with OSA treated with CPAP.
After 30 days of use, secondary objectives are :
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OSA patients treated with CPAP | OSA patient, not previously treated with CPAP, are treated with a "ResMed Airsense 10" CPAP and an "Air Liquide Medical Systems" NINA mask during 30 days, monitored by the home care provider AGIRADOM. After 30 days of CPAP treatment, 4 self-questionnaires are completed by the patient and parameters of the CPAP treatment (compliance, estimated unintentional leakage and therapeutic pressures) are collected. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Self-questionnaire on the comfort and general appreciation of a nasal mask | Other | Self-questionnaire on the comfort and general appreciation of a nasal mask after 30 days of use |
|
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the comfort and general appreciation of a nasal mask | to evaluate, through a questionnaire, the comfort and general appreciation of a nasal mask equipped with a silent leak system and a headgear with adjustment aids, of patients with OSA treated with CPAP. | After 30 days of CPAP treatment |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the appearance of CPAP side effects related to the mask | To evaluate the appearance of CPAP side effects, through a questionnaire, related to the mask (air leaks, injury to the nasal bridge, etc.) | After 30 days of CPAP treatment |
| To collect the patient's appreciation of the mask headgear |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
OSA patient, not previously treated with CPAP, who will be treated with a ResMed Airsense 10 CPAP and an Air Liquide Medical Systems NINA mask Patient whose CPAP treatment will be installed and monitored by the home care provider AGIRADOM.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| LEBRET Marius | AIR LIQUIDE MEDICAL SYSTEMS | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pauline Socquet | Meylan | 38240 | France |
Not provided
Not provided
Not provided
Not provided
| Self-questionnaire on the appearance of CPAP side effects related to the mask | Other | Self-questionnaire on the appearance of CPAP side effects related to the mask (air leaks, injury to the nasal bridge, etc.) after 30 days of use |
|
| Self-questionnaire on the patient's appreciation of the mask headgear, | Other | Self-questionnaire NOSE (Nasal Obstruction Symptom Evaluation) on the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask, after 30 days of use. |
|
| Self-questionnaire NOSE on the discomfort caused by the nasal obstruction | Other | Self-questionnaire NOSE on the discomfort caused by the nasal obstruction reported by the patient, after 30 days of use, compared to the inclusion. |
|
| Self-questionnaire Epworth on the daytime sleepiness | Other | Self-questionnaire Epworth on the daytime sleepiness of the patient, after 30 days of treatment, compared to the inclusion. To study the parameters of the CPAP treatment. |
|
| To study the CPAP compliance | Other | To collect the treatment compliance through telemonitoring of the data recorded by the CPAP machine, during the 30 days of treatment. |
|
| To study the unintentional leakage | Other | To collect the unintentional leakage estimated by the CPAP machine, during the 30 days of treatment. |
|
| To study the therapeutic pressures of CPAP | Other | To collect the therapeutic pressures of CPAP, during the 30 days of treatment. |
|
To collect, through a questionnaire, the patient's appreciation of the mask headgear, which includes indications to help with the installation in the form of graduated markers, as well as the appreciation of the general aesthetics of the mask. |
| After 30 days of CPAP treatment |
| To evaluate the discomfort caused by the nasal obstruction reported by the patient | To evaluate, trough the NOSE questionnaire, the discomfort caused by the nasal obstruction reported by the patient, compared to the inclusion. | After 30 days of CPAP treatment |
| To evaluate the daytime sleepiness of the patient | To evaluate the daytime sleepiness of the patient, through the Epworth questionnaire, compared to the inclusion. | After 30 days of CPAP treatment |
| To collect the CPAP treatment compliance | To collect the treatment compliance (average daily use) through telemonitoring of the data recorded by the CPAP machine. | During the 30 days of CPAP treatment |
| To collect the unintentional leakage | To collect the unintentional leakage estimated by the CPAP machine. | During the 30 days of CPAP treatment |
| To collect the CPAP therapeutic pressures | To collect the CPAP therapeutic pressures used. | During the 30 days of CPAP treatment |
| ID | Term |
|---|---|
| D020181 | Sleep Apnea, Obstructive |
| ID | Term |
|---|---|
| D012891 | Sleep Apnea Syndromes |
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
Not provided
Not provided